Voyager Therapeutics, Inc. , a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system , today announced updates regarding the Phase 1b trial of VY-AADC01 for patients with advanced Parkinson’s disease. “The clinical trial of VY-AADC01 is progressing well with all five patients in Cohort 3 successfully completing treatment,” said Bernard Ravina, M.D., M.S., vice president of clinical development at Voyager Therapeutics.